Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer-Reference-Cited by-同舟云学术

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer

Published:2022-10 Issue:S1 Volume:11 Page:10-16
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Basté Rotllan Neus¹^ORCID

Affiliation:

1. Medical Oncology Department, Hospital Clinic Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona Spain

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5106

Reference52 articles.

1. Aggressive variants of follicular cell derived thyroid carcinoma; the so called ‘Real Thyroid Carcinomas’

2. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial

3. Rationale and design of DECISION: a double‐blind, randomized, placebo‐controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)‐refractory, differentiated thyroid cancer;Brose MS;BMC Cancer,2011

4. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Between the XRCC1, GSTM1, and GSTT1 Polymorphisms in Model of Thyroid Cancer: A Meta-Analysis;Hormone and Metabolic Research;2023-09